New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.
GlaxoSmithKline is back in the hot seat following the release of a US Senate report that highlights serious health risks associated with its diabetes drug Avandia. The report also criticizes the company for its handling of safety data and although GSK has rejected these claims and issued a fierce defense of its drug, the FDA is now under pressure to order the market withdrawal of Avandia.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions